Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Bio-Rad LaboratoriesSTU:BUWA +1.04%71 EV-to-OCF is 20.11 as of Sep. 17, 2026, which is 27% below its 10-year median of 27.37. GuruFocus rates STU:BUWA with a GF Score™ of 71/100 and a GF Value™ of €276.66 (Modestly Overvalued). The stock has 6 warning signs investors should review. Among 852 Medical Devices & Instruments companies, Bio-Rad Laboratories ranks worse than 75.59% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Bio-Rad Laboratories's Enterprise Value is €8,508 Mil.
Bio-Rad Laboratories's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 was €423 Mil. Therefore, Bio-Rad Laboratories's EV-to-OCF for today is 20.11.
The historical rank and industry rank for Bio-Rad Laboratories's EV-to-OCF or its related term are showing as below:
STU:BUWA'
s EV-to-OCF Range Over the Past 10 Years
Min: 11.34 Med: 27.37 Max: 76.3
Current: 19.5
During the past 13 years, the highest EV-to-OCF of Bio-Rad Laboratories was 76.30. The lowest was 11.34. And the median was 27.37.
STU:BUWA's EV-to-OCF is ranked worse than 75.59% of 852
companies
in the Medical Devices & Instruments industry
Industry Median: 7.865
vs STU:BUWA: 19.50
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Bio-Rad Laboratories's PE Ratio (TTM) for today is calculated as:
Bio-Rad Laboratories's share price for today is €330.80.
Bio-Rad Laboratories's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €7.234.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Bio-Rad Laboratories EV-to-OCF Related Terms
Bio-Rad Laboratories EV-to-OCF Historical Data
* Premium members only.
The historical data trend for Bio-Rad Laboratories's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:BUWA vs PODD, GKOS, GMED: EV-to-OCF Comparison
For the Medical Devices subindustry, Bio-Rad Laboratories's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bio-Rad Laboratories EV-to-OCF vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Bio-Rad Laboratories's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Bio-Rad Laboratories's EV-to-OCF falls into.
Bio-Rad Laboratories's current Enterprise Value is €8,508 Mil.
Bio-Rad Laboratories's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €423 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bio-Rad Laboratories (STU:BUWA) has a EV-to-OCF of 20.11 as of Sep. 17, 2026. This is 27% below median its historical median of 27.37. Over the past decade, Bio-Rad Laboratories' EV-to-OCF has ranged from 11.34 to 76.30. According to the industry distribution chart, Bio-Rad Laboratories ranks #644 out of 852 companies in the Medical Devices & Instruments industry, placing it in the top 75.6%.
Is Bio-Rad Laboratories' EV-to-OCF too high?
Bio-Rad Laboratories' current EV-to-OCF of 20.11 is 27% below median its 10-year median of 27.37. Over the past 10 years, this metric has ranged from a low of 11.34 to a high of 76.30. The Medical Devices & Instruments industry median EV-to-OCF is 7.87. Bio-Rad Laboratories' value of 20.11 is 155.7% above this industry median. Based on the distribution chart, Bio-Rad Laboratories ranks #644 out of 852 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Bio-Rad Laboratories has a GF Score™ of 71/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Bio-Rad Laboratories' EV-to-OCF compare to PODD and GKOS?
According to the Medical Devices & Instruments industry distribution chart, Bio-Rad Laboratories ranks #644 out of 852 companies for EV-to-OCF. This places Bio-Rad Laboratories in the lower half of its industry. The industry median EV-to-OCF is 7.87. Bio-Rad Laboratories' value of 20.11 is 155.7% above this benchmark. Historically, Bio-Rad Laboratories' own EV-to-OCF has ranged from 11.34 to 76.30 over the past decade. While the company's 10-year median is 27.37 vs. the industry median of 7.87, Bio-Rad Laboratories has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Medical Devices & Instruments company?
The median EV-to-OCF among Medical Devices & Instruments companies is 7.87, based on 852 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-OCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bio-Rad Laboratories's current EV-to-OCF of 20.11 is 155.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median EV-to-OCF is 7.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bio-Rad Laboratories's current EV-to-OCF is 20.11, which is 27% below median its own 10-year median of 27.37. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bio-Rad Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Bio-Rad Laboratories (STU:BUWA) is currently considered Modestly Overvalued. The stock's GF Value™ is €276.66, compared to a current price of €330.80 — trading 19.6% above its estimated fair value. The current EV-to-OCF is 20.11, which is 27% below median its 10-year median of 27.37 and 155.7% above the Medical Devices & Instruments industry median of 7.87. Bio-Rad Laboratories' overall GF Score™ is 71/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Bio-Rad Laboratories (STU:BUWA), the current EV-to-OCF is 20.11 as of Sep. 17, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bio-Rad Laboratories (STU:BUWA) Overvalued in 2026?
Based on GuruFocus' analysis, Bio-Rad Laboratories stock appears to be overvalued.
The current stock price of €330.80 is trading 19.6% above its estimated GF Value™ of €276.66.
GuruFocus considers Bio-Rad Laboratories to be Modestly Overvalued.
Key valuation signals for STU:BUWA:
EV-to-OCF: 20.11 (27% below median its 10-year median of 27.37)
GF Value™: €276.66 vs. price of €330.80 (19.6% above fair value)
Industry Position: 155.7% above the Medical Devices & Instruments median (#644 of 852)
No single metric tells the full story. See the STU:BUWA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.
71GF Score
Get the complete analysis for STU:BUWA
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:BUWA has been successfully added to your 
